10-Q: Applied Therapeutics Faces Going Concern Amid FDA Setbacks

Applied Therapeutics reports significant losses and a going concern warning following FDA rejection of its lead drug for Classic Galactosemia and ongoing litigation.

Summary

• Applied Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $43.2 million for the six months ended June 30, 2025, a reduction from $81.0 million in the same period of 2024.
• Cash and cash equivalents significantly decreased to $30.4 million as of June 30, 2025, down from $79.4 million at December 31, 2024.
• The company received a Complete Response Letter (CRL) from the FDA in November 2024 for govorestat (AT-007) for Classic Galactosemia, citing deficiencies in the clinical application and failure to reach statistical significance on primary endpoints.
• The FDA also issued Warning Letters to the company and a clinical investigator related to the Phase 2/3 ACTION-Galactosemia Kids study, citing compliance issues and a dosing error.
• The Marketing Authorization Application (MAA) for AT-007 for Classic Galactosemia was withdrawn from the European Medicines Agency (EMA).
• Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern within one year.
• The company out-licensed AT-001 for Diabetic Cardiomyopathy (DbCM) to Biossil, Inc. for an upfront payment of $1.0 million, plus future royalties and milestone payments.
• Analysis of data from the Phase 2/3 INSPIRE trial for AT-007 in CMT-SORD is ongoing, with plans to meet with the FDA in Q3 2025 regarding a potential NDA submission.
• A previously identified material weakness in internal control over financial reporting was fully remediated as of June 30, 2025.
• The company is facing securities class action and shareholder derivative litigation, leading to increased legal and professional fees of $14.5 million for the six months ended June 30, 2025.
• Received a Nasdaq deficiency letter for its bid price, indicating a risk of delisting if compliance is not regained.

Sentiment

Score: 3

Explanation: The company faces severe financial distress with a 'going concern' warning and rapidly depleting cash reserves. Major regulatory setbacks for its lead candidate (govorestat) in Classic Galactosemia, including a Complete Response Letter and Warning Letter from the FDA, cast serious doubt on its near-term commercialization prospects. While there are ongoing efforts for other indications and a recent out-licensing deal, these are insufficient to offset the immediate and substantial risks. The ongoing securities litigation and Nasdaq delisting threat further compound the negative outlook.

Positives

• Net loss for the six months ended June 30, 2025, significantly reduced to $43.2 million compared to $81.0 million in the prior year period.
• Successfully out-licensed AT-001 to Biossil, Inc. for an upfront payment of $1.0 million and eligibility for future royalties and milestone payments, providing non-dilutive funding.
• Remediated a previously reported material weakness in internal control over financial reporting as of June 30, 2025, indicating improved financial controls and governance.
• Presented full 12-month clinical data and new topline 18-month and 24-month data from the INSPIRE Phase 3 trial of AT-007 in CMT-SORD, with plans for a Q3 2025 FDA meeting regarding potential NDA submission.
• AT-001 demonstrated a strong trend in stabilizing cardiac functional capacity in the ARISE-HF study, with a statistically significant improvement in a pre-specified subgroup (p=0.040).

Negatives

• Significant decrease in cash and cash equivalents from $79.4 million at December 31, 2024, to $30.4 million at June 30, 2025.
• Incurred a net loss of $43.2 million for the six months ended June 30, 2025, and has an accumulated deficit of $617.4 million.
• Substantial doubt exists regarding the company's ability to continue as a going concern within one year.
• Received a Complete Response Letter (CRL) from the FDA for govorestat (AT-007) for Classic Galactosemia, indicating non-approval due to clinical application deficiencies and failure to meet primary endpoints.
• FDA issued Warning Letters to the company and a clinical investigator related to the ACTION-Galactosemia Kids study, citing compliance issues and a dosing error.
• Withdrew Marketing Authorization Application (MAA) to the EMA for AT-007 for Classic Galactosemia.
• Increased legal and professional fees by $14.5 million for the six months ended June 30, 2025, primarily due to securities class action and shareholder derivative litigation and responses to FDA letters.
• Received a Nasdaq deficiency letter for its bid price, risking delisting if compliance is not regained.
• Revenue from research and development services decreased to $0 for the six months ended June 30, 2025, from $0.3 million in the prior year.
• Departure of founder and CEO, Dr. Shoshana Shendelman, and other board/management changes, creating uncertainty.

Risks

• Incurred and expect to continue incurring substantial operating losses; may never achieve or maintain profitability.
• Substantial doubt about the ability to continue as a going concern.
• Requires substantial additional funding to finance operations; failure to secure it could force delays or termination of development programs.
• Raising additional capital may cause dilution to stockholders or restrict operations.
• The Warning Letter from the FDA could impede current and future clinical trials or NDA submissions, potentially leading to the FDA's Application Integrity Policy.
• Success is substantially dependent on the successful clinical development, regulatory approval, and commercialization of product candidates; failure to do so will adversely affect the business.
• Received a Complete Response Letter from the FDA for govorestat for Classic Galactosemia; no guarantee of future regulatory approval for any indication.
• May fail to perform under partnership agreements (e.g., Advanz Pharma), potentially leading to liabilities and unachieved benefits.
• Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials, and results may not be sufficient for necessary regulatory approvals.
• Clinical drug development is a lengthy, expensive, and uncertain process, potentially leading to additional costs, delays, or difficulties.
• May be unable to obtain or maintain regulatory approvals, designations, or accelerated pathways for product candidates.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial potential, or result in negative consequences post-approval.
• Interim, top-line, and preliminary data from clinical trials are subject to change as more patient data becomes available and are subject to audit and verification procedures.
• Market opportunities for product candidates may be smaller than anticipated, or any approval obtained may be based on a narrower definition of the patient population.
• Faces substantial competition from pharmaceutical and biotechnology companies with greater resources and experience.
• Risks related to strategic collaborations, including lack of control, disputes, or termination.
• Sudden changes in regulatory standards could impact the acceptability of clinical studies to support approval.
• Even if approved, products may fail to achieve market acceptance by physicians, patients, or third-party payors.
• Insurance policies may be inadequate, potentially exposing the company to unrecoverable risks.
• Relationships with customers, physicians, and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and privacy laws; noncompliance carries substantial penalties.
• Coverage and adequate reimbursement may not be available for product candidates, making profitable sales difficult.
• Healthcare reform measures may negatively impact business and results of operations.
• One of the clinical investigators received a warning letter from the FDA following a site inspection; similar issues at other sites could negatively impact the clinical program.
• Relies on third parties to conduct, supervise, and monitor preclinical studies and clinical trials; unsatisfactory performance may harm the business.
• Relies on third parties to produce clinical and commercial supplies of product candidates; risks include inability to meet specifications, capacity issues, and compliance failures.
• Business involves hazardous materials; compliance with environmental, health, and safety laws and regulations can be expensive and interrupt business.
• Breaches of license agreements (e.g., Columbia University, University of Miami) could result in the loss of ability to continue development and commercialization of related products.
• Insufficient patent protection could allow competitors to develop similar products.
• Obtaining and maintaining patent rights is expensive, complicated, and labor-intensive; patent terms may be inadequate.
• May be subject to claims alleging infringement, misappropriation, or other violations of intellectual property rights.
• Changes in U.S. patent law or the patent law of other countries could diminish the value of patents.
• May not be able to protect intellectual property rights throughout the world.
• Reliance on third parties requires sharing trade secrets, increasing the possibility of discovery or misappropriation.
• Trademarks may be infringed or successfully challenged.
• Intellectual property rights do not necessarily address all potential threats to the business.
• Involved in securities-related class action and derivative litigation, which could be costly, divert resources, and damage reputation.
• Recent leadership changes, including the former founder and CEO's departure, may create uncertainty.
• May experience difficulties resulting from the expansion of the organization.
• Internal computer systems, or those of collaborators, may fail or suffer security breaches.
• The market price of common stock is volatile and has fluctuated substantially, which could result in substantial losses for purchasers.
• Failure to regain compliance with Nasdaq continued listing requirements could result in delisting.
• Does not anticipate paying cash dividends; capital appreciation, if any, will be the sole source of gain.
• Future sales of common stock by holders, or the perception of such sales, could depress the market price.
• If research analysts do not publish research or publish unfavorable reports, stock price and trading volume could decline.
• Broad discretion in the use of cash and cash equivalents, which may be used ineffectively.
• No longer qualifies as an emerging growth company, resulting in increased disclosure and compliance requirements.
• Incurred increased costs as a result of operating as a public company, requiring substantial management time.
• The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect the business.
• Provisions in corporate charter documents and under Delaware law could make an acquisition more difficult and may prevent attempts by stockholders to replace or remove current management.
• Governing documents designate certain courts as the sole and exclusive forum for certain types of actions and proceedings, which could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company is actively working to address the issues raised in the FDA's Complete Response Letter and Warning Letter for govorestat in Classic Galactosemia. It is continuing to analyze data from the Phase 2/3 INSPIRE trial for AT-007 in CMT-SORD and plans to meet with the FDA in Q3 2025 regarding a potential NDA submission for this indication. The company anticipates potential moderate growth in its clinical development and operations teams to support additional clinical trials and preparations for commercialization. It expects to continue incurring significant expenses and increasing operating losses for the foreseeable future and will need substantial additional funding, actively pursuing various financing options and business development opportunities.

Management Comments

• "Actively working to address the issues raised in the Complete Response Letter and Warning Letter."
• "Continuing to analyze the data from the Phase 2/3 INSPIRE trial and the extent to which these data may support a potential submission for regulatory approval, including under the accelerated approval pathway."
• "Plan to meet with the FDA in the third quarter of 2025 regarding a potential NDA submission for govorestat for the treatment of CMT-SORD."
• "Anticipate potential moderate growth in our clinical development and operations teams to support the additional clinical trials to support the late stage indications and preparations for commercialization."
• "Expect to continue to incur significant expenses and increasing operating losses for the foreseeable future."
• "We have concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these unaudited condensed financial statements are issued."
• "Management has determined that these controls operated effectively in the first two quarters of 2025 and concluded that material weakness was fully remediated as of June 30, 2025."

Industry Context

Applied Therapeutics operates in the highly competitive clinical-stage biopharmaceutical industry, specializing in novel product candidates for rare diseases. Its primary focus is on Aldose Reductase (AR) inhibition, a molecular target that has historically presented challenges for drug development due to nonselective inhibition. The company targets diseases with high unmet medical needs, such as Classic Galactosemia (no approved treatments), CMT-SORD, PMM2-CDG (a rare pediatric disease with high mortality), and Diabetic Cardiomyopathy (DbCM, a fatal heart fibrosis with no available treatments). The industry is characterized by lengthy and expensive development processes, high regulatory hurdles, and intense competition from larger, more established companies. The company's recent regulatory setbacks with the FDA for its lead candidate highlight the inherent risks in drug development, particularly for novel mechanisms or rare indications. The out-licensing of AT-001 is a common strategy for smaller biotechs to manage pipeline assets and secure non-dilutive funding, while the ongoing financial challenges and 'going concern' warning reflect the typical capital intensity and financial fragility of clinical-stage companies prior to commercialization.

Comparison to Industry Standards

• The company's significant cash burn and 'going concern' warning are common for clinical-stage biopharmaceutical companies that have not yet commercialized products, but the magnitude of the cash decline and the explicit going concern statement indicate a heightened level of financial risk compared to peers with stronger cash positions or clearer paths to revenue.
• The FDA's Complete Response Letter (CRL) and Warning Letter for a lead candidate (govorestat for Classic Galactosemia) represent a severe setback, more impactful than typical clinical trial delays, and suggest significant challenges in meeting regulatory standards, which is a critical concern for a company reliant on a limited pipeline.
• The out-licensing of AT-001 to Biossil, Inc. for an upfront payment and future milestones is a standard industry practice for smaller biotechs to de-risk and monetize assets, allowing focus on core programs, but the relatively small upfront payment ($1.0 million) suggests a limited valuation for the asset at this stage.
• The ongoing securities class action and shareholder derivative litigation, stemming from regulatory setbacks and management changes, are indicative of the high scrutiny and legal risks faced by public biopharmaceutical companies, especially when significant negative events occur.
• The Nasdaq bid price deficiency is a common challenge for smaller, volatile biotech stocks, and failure to resolve it could lead to delisting, further impacting liquidity and investor confidence, a risk many smaller industry players face.

Management Changes

Corporate Governance

Legal Proceedings

• Securities Class Action Litigation: Two putative class action lawsuits (Alexandru v. Applied Therapeutics, Inc., et al. and Ikram v. Applied Therapeutics, Inc., et al.) filed in December 2024, consolidated on March 11, 2025. Allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 for false and/or misleading statements related to the govorestat NDA for Classic Galactosemia. Seek unspecified damages. Motions to dismiss were pending as of July 18, 2025.
• Shareholder Derivative Litigation: Hassine v. Shendelman, et al., filed January 31, 2025, against certain current and former officers and directors. Alleges derivative claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, violations of Section 14(a) and contribution under Sections 10(b) and 21D of the Exchange Act. Seeks corporate governance reforms, recovery for company liability, and monetary/equitable relief. Temporarily stayed as of March 5, 2025.
• The probability of loss on these lawsuits was determined to be 'reasonably possible' as of June 30, 2025, but the amount or range of loss is not currently estimable.

Related Party Transactions

• The company had a LaunchLabs Agreement with ARELaunchLabs NYC LLC, a subsidiary of Alexandria Real Estate Equities, Inc., where a shareholder and former board member is the founder and executive chairman. Payments made were $0 for the three months ended June 30, 2025, and $17,000 for the six months ended June 30, 2025. The agreement was terminated as of January 31, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future capital raises, further stock price decline due to regulatory setbacks and litigation, and the risk of delisting from Nasdaq. The 'going concern' warning indicates a risk of losing their entire investment.
• Employees may experience uncertainty due to recent management changes, including the CEO's departure, but there is an anticipation of moderate growth in clinical development and operations teams if programs advance.
• Patients, particularly those with Classic Galactosemia, face continued lack of an approved treatment due to the FDA's Complete Response Letter, while patients with CMT-SORD await potential NDA submission.
• Creditors face increased risk due to the company's 'going concern' status and significant cash burn.
• Suppliers and partners, including CROs, CMOs, and licensing partners like Advanz Pharma and Biossil, could be impacted by potential delays or termination of drug development programs.

Next Steps

• Actively work to address issues raised in the FDA's Complete Response Letter and Warning Letter.
• Continue to analyze data from the Phase 2/3 INSPIRE trial for AT-007 in CMT-SORD.
• Plan to meet with the FDA in Q3 2025 regarding a potential NDA submission for govorestat for CMT-SORD.
• Pursue additional long-term financing options, including equity, debt, convertible debt, and synthetic royalty financing.
• Pursue business development opportunities related to one or more programs.
• Continue efforts to improve control processes and maintain effective internal control over financial reporting.
• Address Nasdaq bid price deficiency to regain compliance or transfer listing to the Nasdaq Capital Market.

Key Dates

Recommendation

The company faces severe financial distress with a 'going concern' warning and rapidly depleting cash reserves. The FDA's Complete Response Letter and Warning Letter for its lead candidate (govorestat for Classic Galactosemia) are major setbacks, indicating significant regulatory hurdles and potential delays or abandonment of a key program. While there are ongoing efforts for other indications and a recent out-licensing deal, these are insufficient to offset the immediate and substantial risks. The ongoing securities litigation and Nasdaq delisting threat further compound the negative outlook, making the stock a high-risk investment with significant downside potential.

Keywords

Biopharmaceutical, Rare Diseases, Galactosemia, SORD Deficiency, Diabetic Cardiomyopathy, Aldose Reductase Inhibitor, Clinical Stage, FDA Approval, SEC Filing, Drug Development, Biotech, Clinical Trials, Orphan Drug, Going Concern, Litigation, Nasdaq Listing